Company

BioMarin Pharmaceutical Inc.

Headquarters: San Rafael, CA, United States

Founded: March 1997

Employees: 3,045

CEO: Mr. Jean-Jacques Bienaime M.B.A., MBA

NASDAQ: BMRN -2.36%

Market Cap

$18.41 Billion

USD as of Jan. 1, 2024

history Market Cap History

BioMarin Pharmaceutical Inc. market capitalization over time

Evolution of BioMarin Pharmaceutical Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of BioMarin Pharmaceutical Inc.

Detailed Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

BioMarin Pharmaceutical Inc. has the following listings and related stock indices.


Stock: NASDAQ: BMRN wb_incandescent

Stock: BMV: BMRN wb_incandescent

Stock: Bovespa: B1MR34 wb_incandescent

Stock: XETR: BM8 wb_incandescent

Product & Services

KuvanNaglazymeAldurazymeFirdapseVimizimBrineuraPalynziq

Key People

Founder(s): Christopher Starr, Ph. D. Grant W. Denison Jr.

Jean- Jacques Bienaimé (Chairman & CEO) Daniel Spiegelman (Executive VP & CFO) Brian R. Mueller (Senior VP, Finance & CAO)

Financials

Revenue: US$1.860 Billion (Fiscal Year Ended December 31, 2020)

Operating income: –US$36.765 Million (Fiscal Year Ended December 31, 2020)

Net income: US$0.859 Billion (Fiscal Year Ended December 31, 2020)


Total assets: US$5.848 Billion (Fiscal Year Ended December 31, 2020)

Total equity: US$4.106 Billion (Fiscal Year Ended December 31, 2020)

Details

Headquarters:

770 Lindaro Street

San Rafael, CA 94901

United States

Phone: 415 506 6700